These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 32175799)

  • 21. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands.
    Stern ME; Beuerman RW; Fox RI; Gao J; Mircheff AK; Pflugfelder SC
    Cornea; 1998 Nov; 17(6):584-9. PubMed ID: 9820935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model.
    Kim CE; Kleinman HK; Sosne G; Ousler GW; Kim K; Kang S; Yang J
    Sci Rep; 2018 Jul; 8(1):10500. PubMed ID: 30002412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Outcomes of Lifitegrast 5% Ophthalmic Solution in the Treatment of Dry Eye Disease.
    Tong AY; Passi SF; Gupta PK
    Eye Contact Lens; 2020 Jan; 46 Suppl 1():S20-S24. PubMed ID: 30985492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topical corticosteroids for dry eye.
    Liu SH; Saldanha IJ; Abraham AG; Rittiphairoj T; Hauswirth S; Gregory D; Ifantides C; Li T
    Cochrane Database Syst Rev; 2022 Oct; 10(10):CD015070. PubMed ID: 36269562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reconsidering the central role of mucins in dry eye and ocular surface diseases.
    Baudouin C; Rolando M; Benitez Del Castillo JM; Messmer EM; Figueiredo FC; Irkec M; Van Setten G; Labetoulle M
    Prog Retin Eye Res; 2019 Jul; 71():68-87. PubMed ID: 30471351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Keratitis in Dry Eye Disease and Topical Ciclosporin A.
    Leonardi A; Flamion B; Baudouin C
    Ocul Immunol Inflamm; 2017 Aug; 25(4):577-586. PubMed ID: 28146363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging therapies for dry eye disease.
    Mason L; Jafri S; Dortonne I; Sheppard JD
    Expert Opin Emerg Drugs; 2021 Dec; 26(4):401-413. PubMed ID: 34846978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting.
    Baudouin C; Aragona P; Messmer EM; Tomlinson A; Calonge M; Boboridis KG; Akova YA; Geerling G; Labetoulle M; Rolando M
    Ocul Surf; 2013 Oct; 11(4):246-58. PubMed ID: 24112228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjögrens syndrome-like MRL/lpr mice.
    Gao J; Morgan G; Tieu D; Schwalb TA; Luo JY; Wheeler LA; Stern ME
    Exp Eye Res; 2004 Apr; 78(4):823-35. PubMed ID: 15037117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluating the novel application of cyclosporine 0.1% in ocular surface disease.
    Boboridis KG; Konstas AGP
    Expert Opin Pharmacother; 2018 Jun; 19(9):1027-1039. PubMed ID: 29847195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of topical cyclosporine 0.05% and osmoprotective lubricating eye drops in treating dry eye disease and inflammation.
    Mullick R; Annavajjhala S; Thakur P; Mohapatra A; Shetty R; D'Souza S
    Indian J Ophthalmol; 2021 Dec; 69(12):3473-3477. PubMed ID: 34826977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
    Holland EJ; Luchs J; Karpecki PM; Nichols KK; Jackson MA; Sall K; Tauber J; Roy M; Raychaudhuri A; Shojaei A
    Ophthalmology; 2017 Jan; 124(1):53-60. PubMed ID: 28079022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TRI Microspheres prevent key signs of dry eye disease in a murine, inflammatory model.
    Ratay ML; Balmert SC; Acharya AP; Greene AC; Meyyappan T; Little SR
    Sci Rep; 2017 Dec; 7(1):17527. PubMed ID: 29235530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lifitegrast Ophthalmic Solution 5.0% for Treatment of Dry Eye Disease: Overview of Clinical Trial Program.
    Chan CC; Prokopich CL
    J Pharm Pharm Sci; 2019; 22(1):49-56. PubMed ID: 30636670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short term effects of topical cyclosporine and viscoelastic on the ocular surfaces in patients with dry eye.
    Moon JW; Lee HJ; Shin KC; Wee WR; Lee JH; Kim MK
    Korean J Ophthalmol; 2007 Dec; 21(4):189-94. PubMed ID: 18063881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sjögren's syndrome associated dry eye in a mouse model is ameliorated by topical application of integrin α4 antagonist GW559090.
    Contreras-Ruiz L; Mir FA; Turpie B; Krauss AH; Masli S
    Exp Eye Res; 2016 Feb; 143():1-8. PubMed ID: 26463157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease.
    Sacchetti M; Mantelli F; Lambiase A; Mastropasqua A; Merlo D; Bonini S
    Br J Ophthalmol; 2014 Aug; 98(8):1016-22. PubMed ID: 24344232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular evidence for the role of inflammation in dry eye disease.
    Ganesalingam K; Ismail S; Sherwin T; Craig JP
    Clin Exp Optom; 2019 Sep; 102(5):446-454. PubMed ID: 30630216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management Strategies for Evaporative Dry Eye Disease and Future Perspective.
    Rolando M; Merayo-Lloves J
    Curr Eye Res; 2022 Jun; 47(6):813-823. PubMed ID: 35521685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease.
    Wang Y; Ogawa Y; Dogru M; Kawai M; Tatematsu Y; Uchino M; Okada N; Igarashi A; Kujira A; Fujishima H; Okamoto S; Shimazaki J; Tsubota K
    Bone Marrow Transplant; 2008 Feb; 41(3):293-302. PubMed ID: 17982500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.